Abstract

The scientific advances described in earlier chapters have inevitably triggered a response in the world of business and economics, and in this chapter I consider the recent activities of the American company, Celera Genomics, which aims to obtain patent rights for aspects of the human genome. This brings into question whether life, indeed human life, should belong to anyone or anybody. It raises, too, the further question as to how this new information will be used.